Key Insights

Highlights

Success Rate

86% trial completion

Published Results

23 trials with published results (9%)

Research Maturity

110 completed trials (43% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

7.1%

18 terminated out of 253 trials

Success Rate

85.9%

-0.6% vs benchmark

Late-Stage Pipeline

17%

44 trials in Phase 3/4

Results Transparency

21%

23 of 110 completed with results

Key Signals

23 with results86% success18 terminated

Data Visualizations

Phase Distribution

158Total
Not Applicable (75)
Early P 1 (2)
P 1 (15)
P 2 (22)
P 3 (19)
P 4 (25)

Trial Status

Completed110
Unknown55
Recruiting45
Terminated18
Not Yet Recruiting14
Active Not Recruiting5

Trial Success Rate

85.9%

Benchmark: 86.5%

Based on 110 completed trials

Clinical Trials (253)

Showing 20 of 20 trials
NCT02514226Not ApplicableCompletedPrimary

Evaluation of Periodontal Treatment in Patients With Bronchiectasis

NCT05238675Phase 2CompletedPrimary

A Study to Test Whether Different Doses of BI 1291583 Help People With Bronchiectasis

NCT06872892Phase 3RecruitingPrimary

The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

NCT05846230Phase 2Active Not RecruitingPrimary

Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine

NCT00943514RecruitingPrimary

Natural History of Bronchiectasis

NCT07201051Phase 2RecruitingPrimary

A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis

NCT02804971CompletedPrimary

Cardiovascular Comorbidities and Bronchiectasis

NCT07577804Phase 3Not Yet RecruitingPrimary

A Study to Evaluate the Efficacy and Safety of CHF10196 Tablets (Florensocatib) Compared With Placebo in Male and Female Participants 12 to 85 Years of Age With Bronchiectasis

NCT05865886Phase 2Completed

A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™)

NCT05351242Not ApplicableNot Yet Recruiting

THERMotherapy Against Persistent Bacterial LUNG Infections

NCT07647575Not ApplicableRecruiting

Hypertonic Saline Inhalation for Nontuberculous Mycobacterial Lung Disease

NCT07648082Recruiting

Breathlessness Perceptions Within Respiratory Diseases

NCT07631507Not Yet Recruiting

A Study to Evaluate the Diagnostic Performance of Portable Oscillometry Across Chronic Respiratory Diseases

NCT07283497Phase 4RecruitingPrimary

Itraconazole Therapy In Bronchiectasis With Airway Mold

NCT07608328Phase 4Not Yet Recruiting

Azithromycin to Modify Bronchiectasis Exacerbation Risk

NCT07599839RecruitingPrimary

BASE: Bronchiectasis Severity and Exacerbation Risk Study

NCT07599969RecruitingPrimary

Bronchiectasis Phenotype Identification Model

NCT07192705Recruiting

Health Impact of Non-Tuberculous Mycobacteria Pulmonary Disease (NTM-PD)

NCT05783869RecruitingPrimary

Study of Bronchiectasis and Associated Cardiovascular Comorbidities

NCT06983366Recruiting

Validation and Clinical Utility of the Lung Sliding Index (LSI) for Differentiating Pulmonary Diseases

Scroll to load more

Research Network

Activity Timeline